Maintenance of protein homeostasis is a critical function of the cell, and disruptions of this process contribute to the development of numerous diseases, including cancer.1-3 Ubiquitination and degradation of proteins is a key component of protein homeostasis, and proteins involved in this process, including E3 ubiquitin ligases, are increasingly being investigated as therapeutic targets.2,3
Celgene is developing cancer treatments directed at key biological pathways in protein homeostasis.
Pursuing Next-Generation Therapies That Target Critical Pathways in Protein Homeostasis
Sontag EM, et al. Curr Opin Cell Biol. 2014;26:139-146.
García-Santisteban I, et al. Mol Cancer. 2013;12:91.
Sévère N, et al. Cell Death Dis. 2013;4:e463.
Gandhi AK, et al. Br J Haematol. 2014;164:811-821.
Kronke J, et al. Science. 2014;343:301-305.
Lu G, et al. Science. 2014;343:305-309.
Please Keep Me Informed
Provide your email address to receive monthly updates on Celgene’s research, news, and developments.
To view To return to www.researchoncology.com